NBY — NovaBay Pharmaceuticals Share Price
Last trade - 00:00- $2.72m
- $2.68m
- $14.73m
- 21
- 51
- 54
- 37
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.99 | ||
| Price to Tang. Book | 1.99 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.18 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -159.71% | ||
| Return on Equity | -373.33% | ||
| Operating Margin | -51.58% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.6 | 9.93 | 8.42 | 14.4 | 14.73 | 16.1 | 21.57 | 3.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and wound care products. Its product, Avenova Antimicrobial Lid and Lash Solution, has antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. It offers a portfolio of products for each step of the standard at home treatment regimen, including the Avenova Eye Health Support antioxidant-rich oral supplement, Avenova Lubricating Eye Drops for instant relief, NovaWipes by Avenova, Avenova Warm Eye Compress to soothe the eyes, and the i-Chek by Avenova to monitor physical eyelid health. It also manufactures and sells its proprietary form of hypochlorous acid for the wound care market with its NeutroPhase and PhaseOne branded products. NeutroPhase and PhaseOne are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers and other injuries.
Directors
- Paul Freiman NEC (86)
- Justin Hall CEO (43)
- Andrew Jones CFO (50)
- Audrey Kunin OTH (62)
- Mijia Wu DRC (46)
- Yongxiang Zheng DRC (52)
- Julie Garlikov IND (51)
- Swan Sit IND (44)
- Yenyou Zheng IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 19th, 2010
- Public Since
- October 26th, 2007
- No. of Shareholders
- 114
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 30,098,150
- Address
- 2000 Powell St Ste 1150, EMERYVILLE, 94608-1804
- Web
- https://novabay.com/
- Phone
- +1 5108998800
- Contact
- Jody Cain
- Auditors
- WithumSmith Brown PC
Latest News for NBY
Upcoming Events for NBY
Q1 2024 NovaBay Pharmaceuticals Inc Earnings Release
NovaBay Pharmaceuticals Inc Annual Shareholders Meeting
NovaBay Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 NovaBay Pharmaceuticals Inc Earnings Release
Similar to NBY
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
AIM ImmunoTech
NYSE MKT
Ampio Pharmaceuticals
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
FAQ
As of Today at 19:15 UTC, shares in NovaBay Pharmaceuticals are trading at $0.09. This share price information is delayed by 15 minutes.
Shares in NovaBay Pharmaceuticals last closed at $0.09 and the price had moved by -94.3% over the past 365 days. In terms of relative price strength the NovaBay Pharmaceuticals share price has underperformed the S&P500 Index by -95.39% over the past year.
The overall consensus recommendation for NovaBay Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
NovaBay Pharmaceuticals does not currently pay a dividend.
NovaBay Pharmaceuticals does not currently pay a dividend.
NovaBay Pharmaceuticals does not currently pay a dividend.
To buy shares in NovaBay Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.09, shares in NovaBay Pharmaceuticals had a market capitalisation of $2.72m.
Here are the trading details for NovaBay Pharmaceuticals:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: NBY
Based on an overall assessment of its quality, value and momentum NovaBay Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in NovaBay Pharmaceuticals is $3.35. That is 3605.75% above the last closing price of $0.09.
Analysts covering NovaBay Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.41 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like NovaBay Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -79.7%.
As of the last closing price of $0.09, shares in NovaBay Pharmaceuticals were trading -75.21% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The NovaBay Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.09.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
NovaBay Pharmaceuticals' management team is headed by:
- Paul Freiman - NEC
- Justin Hall - CEO
- Andrew Jones - CFO
- Audrey Kunin - OTH
- Mijia Wu - DRC
- Yongxiang Zheng - DRC
- Julie Garlikov - IND
- Swan Sit - IND
- Yenyou Zheng - IND